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ABSTRACT
Objectives To determine if a topically applied non-
steroidal anti-inflammatory drug (diclofenac) can provide 
short-term pain relief for chronic Achilles tendinopathy 
(CAT), in order to inform the development of a new 
rehabilitation protocol.
Design and setting Pilot double-blind, cross-over 
randomised controlled trial providing participants with 
tertiary care. The study was conducted at a single research 
centre in Vancouver, BC.
Participants Sixteen adults with unilateral CAT and three 
adults with bilateral CAT participated.
Interventions Participants received two successive 
treatments (10% diclofenac gel or placebo gel) in random 
order over a 3-day period. There was a 1-week washout 
period between the treatments. Allocation was by simple 
randomisation, and the participants as well as the 
assessing/treating researcher were blinded to treatment 
allocation.
Outcome measures The primary outcome measure 
was pain level (0–10) during tendon loading (hopping). 
Secondary outcome measures included pain at rest, 
pressure pain threshold of the Achilles tendon and 
symptom improvement.
Results Nineteen adults participated in the study, 
and all were included in the analysis. Diclofenac gel 
significantly reduced the average pain during tendon 
loading (p<0.001) and at rest (p=0.031). The average 
baseline hopping pain was 4.8/10 (95% CI 3.92 to 5.68) 
and was reduced to 3.1/10 (2.35–3.85) by diclofenac. 
Pain at rest was decreased and pressure pain threshold 
increased with diclofenac treatment, but not with placebo 
gel. There were no observed or reported side effects of 
either treatment.
Conclusions In this small, short-term study, diclofenac 
was able to improve symptoms and reduce pain during 
tendon loading in participants with CAT, whereas placebo 
gel was not. A future study of diclofenac as a supplement 
to rehabilitation, with longer follow-up and powered to 
detect a difference between diclofenac and placebo, is 
indicated.
Trial registration ISRCTN60151284, http://www. isrctn. 
com/ ISRCTN60151284
Ethics UBC Clinical Research Ethics Board approval was 
obtained for this research. The certificate number of the 
ethics certificate of approval to conduct research is H15-
00999.
INTRODUCTION
Chronic Achilles tendinopathy (CAT) is char-
acterised by a breakdown and disorganisation 
of collagen fibres, increased tendon blood 
flow, an increase in the amount of non-collag-
enous matrix and resultant chronic pain and 
swelling.1 The condition is often attributed to 
a failure in the tendon’s adaptive and repar-
ative responses following repetitive tendon 
loading, and the pathogenesis may involve 
a chronic low-grade inflammation in the 
tendon and surrounding tissues.2 3 Training at 
excessive or unaccustomed volumes can lead 
to a degradation of the viscoelastic character-
istics of the tendon and an accumulation of 
dysfunctional repair tissue.4 CAT is common 
in athletes that participate in sports involving 
running and jumping, but the condi-
tion also occurs in sedentary, middle-aged 
adults.5 6 The causes and pathogenesis of CAT 
are likely to be diverse and multifactorial in 
many cases: extrinsic factors (such as training 
errors) have been suggested to interact with 
intrinsic factors (such as advancing age, male 
sex, increasing body composition, genetic 
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Strengths and limitations of this study
 ► This study presents preliminary evidence that 
topical diclofenac exerts an analgesic effect on 
chronic Achilles tendon pain.
 ► This was a well-controlled, double-blinded 
experiment conducted in a research setting with no 
dropouts and all data analysed.
 ► Given that full recovery from chronic Achilles 
tendinopathy requires many months and that the 
gold standard of treatment involves exercise-based 
rehabilitation, it is not, by itself, sufficient evidence 
to change practice.
 ► The study was not adequately powered to detect 
significant differences between placebo and 
diclofenac and is of insufficient length to determine 
impact on clinical outcomes.
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predisposition and insufficient muscle strength or flexi-
bility) to predispose to the chronic condition.3 7
One of the long-term goals of rehabilitation is to 
strengthen the injured Achilles tendon enough to with-
stand the same force as a healthy tendon. Various forms 
of exercise including eccentric training, heavy slow 
resistance and a combination of eccentric/concentric 
exercise have been reported to promote the recovery of 
Achilles tendons to healthy states.8 However, chronic pain 
may be a limitation in CAT rehabilitation. It has been 
suggested that allowing the patient to experience pain 
during rehabilitation of CAT appears to have no negative 
effect on overall recovery9 10 and that, in fact, some pain 
may be unavoidable to ensure that the Achilles tendon 
load is sufficient to create meaningful adaptive changes in 
the tendon.11 Nevertheless, in the current study we inves-
tigated the effects of topical diclofenac on patients with 
CAT in order to determine if participants could achieve a 
physiological tendon load (ie, hopping in place) with less 
pain, based on the clinical observation that pain may be 
a limiting factor during rehabilitation, particularly in the 
early stages of recovery.
Diclofenac is a non-steroidal anti-inflammatory drug 
(NSAID) that works by preventing cyclooxygenase from 
synthesising prostaglandins.12 Topical diclofenac has 
been shown to be a safe and effective medicine in treating 
several painful musculoskeletal disorders.13 Topical 
diclofenac is used in osteoarthritis of the knee to reduce 
pain, morning stiffness and improved physical func-
tion. At high tissue concentration, diclofenac can block 
sodium channels and prevent nociceptive afferent action 
potentials.13 Thus, in addition to reducing the levels of 
classic inflammatory substances like prostaglandins E2, 
diclofenac could inhibit other relevant nociceptive mech-
anisms.14
CAT is prevalent in the general population, yet no 
programme has been developed that can successfully 
treat this disorder in all cases, and there are no controlled 
trials to our knowledge of treatments that can success-
fully reduce pain in the short term, although case studies 
have demonstrated the efficacy of individualised biome-
chanical interventions such as taping.15 In order to make 
progress towards the long-term goal of developing more 
effective rehabilitation programmes, we investigated the 
effects of topical diclofenac on individuals with CAT. In 
addition, this study investigated how pain may influence 
exercise performance (eg, force output during single-leg 
hopping at voluntary intensity) in individuals with CAT. 
The objective of this study was to evaluate the potential 
utility of incorporating diclofenac into a larger controlled 
study with a longer treatment course including exer-
cise-oriented rehabilitation.
METHODS
Study design and recruitment
This study was a short-term, pilot cross-over 
randomised controlled trial conducted in a research 
setting. Recruitment occurred for a predetermined 
period from August 2015 to March 2016 and was stopped 
due to the timeline of an investigator’s (EB) academic 
programme. Participants were recruited by placing adver-
tisements in the community. Each participant received 
one of the two treatments (placebo or diclofenac) in 
Figure 1 Experimental procedures. The step-by-step 
outline of study visits (1–4) over 30 days. BMI, body mass 
index
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random order, then after a 1-week wash out period, the 
participant received the other treatment. The purpose 
of the placebo group was to assess the magnitude of 
non-specific effects related to the application of gel and 
interaction with the study team and to blind the assessor 
(EB). Following the registration of the trial but before 
enrolling any patients, additional secondary outcome 
measures were added (pain at rest and change in symp-
toms are described below). Participants volunteered and 
were free to withdraw at any time during the study. No 
compensation was provided for participation in this study.
Experimental procedure
The following procedures were conducted at the 
University of British Columbia Hip Health and Mobility 
(figure 1).
Visit 1
The coinvestigator (EB) met with the participant at their 
intake appointment time to review inclusion/exclusion 
criteria (Box 1), assess interest in study participation and 
answer questions. If the participant agreed, the consent 
form was completed. In order to characterise the level 
of function of enrolled participants, they completed the 
Tegner Activity Level16 and the VISA-A Questionnaire17 
(a self-report questionnaire that measures Achilles tend-
inopathy severity). The screening visit was completed by 
having the participant rate their pain (using a numeric 
pain rating scale (NPRS) from 0 to 10) during 25–28 single-
legged hops at a self-selected pace on each leg18 19 on a 
force plate (Leonardo Mechanograph, Novotec Medical, 
Pforzheim, Germany). On conclusion of the initial visit 
and verification of eligibility criteria (Box 1), the following 
visits were scheduled. The second visit was scheduled after 
a 1-week washout period. Participants were instructed to 
refrain from moderate to vigorous physical activity for 
72 hours prior to the appointment, to refrain from taking 
any NSAIDs for 1 week or other analgesics for 24 hours, to 
receive no new treatment throughout the study and not 
to make any changes to treatment they might already be 
receiving.
Visit 2
The coinvestigator completed the eligibility screen, 
which included data collection (demographic informa-
tion, rehabilitation history and medical questionnaire 
including date of last NSAID taken) and a grey-scale 
ultrasound scan (10 MHz Terason probe, UTC Tech-
nologies scanner, GD Stein, Netherlands) to assess the 
presence of tendinopathic change (scans performed by 
EB and read by AS). Following the ultrasound scan, the 
investigator (EB) used the AlgoMed Algometer (Medoc, 
Ramat Yishai, Israel) to assess the participant’s pressure 
pain threshold (PPT) on the affected Achilles tendon(s). 
Testing was conducted at a controlled rate (30 kPa/s) 
with the participant lying prone on a treatment plinth. 
Pressure was gradually applied until the participant first 
experienced onset of pain, at which point they pushed a 
button to record the PPT. In cases where the person with 
CAT had baseline (resting) pain, they were instructed to 
press the button at the first increase in pain.
Following the PPT measurement, participants were 
asked to rhythmically hop 25–28 times, at a comfortable 
pace and intensity (approximately two jumps per second), 
on one leg, first on the unaffected side, and then on the 
affected side (15 s rest between each leg). At the end of 
the hopping, the participant’s pain level was recorded 
using an NPRS (0–10). Prior to the hopping test, partici-
pants warmed up with 5 min of very light stationary biking 
(no resistance and self-selected pace) and three sets of 10 
two-legged toe raises (60 s rest between sets).
Participants were then issued with either placebo gel 
or 10% diclofenac gel (Medisca, PLO Mediflo 30, an 
opaque gel base with an off-white hue), which were iden-
tical in appearance. A pharmacist uninvolved in the study 
supplied the gel in semiopaque syringes, and the inves-
tigator (EB) and participants did not know the content 
of the tubes supplied. Participants were instructed to 
massage 1 g of the gel on the most painful area of the 
tendon for 30–45 s three times a day at 8-hour intervals 
for 3 days before the next scheduled appointment. They 
were asked to complete a medication administration diary 
to confirm their compliance with the pretest regimen.
Box 1 Inclusion and exclusion criteria
Inclusion criteria
1. Male and female participants aged 19 years and older
2. Fluent in English
3. Participants previously diagnosed with Achilles tendinopathy by a 
healthcare professional and demonstrating the following criteria: 
localised Achilles tendon pain and thickening, worsened with 
palpation and tendon loading activities and no clinical suspicion of 
other diagnoses
4. Symptoms for 3 months or more
5. Participants who are able to give informed consent
6. VISA-A score less than 80
7. Pain score (numeric pain rating scale) greater than 2/10 when 
performing a hopping test (25–28 single-leg hops on the painful 
side)
Exclusion criteria
1. Male and female participants aged 18 years and younger
2. Participants with a BMI greater than 30.0
3. Participants with previous Achilles tendon rupture
4. Participants diagnosed with chronic pain syndrome, diabetes, 
hyperproteinaemia, metabolic syndrome or systemic inflammatory 
diseases
5. Participants with symptomatic osteoarthritis of the spine or lower 
extremities
6. Participants who have received corticosteroid injections
7. Participants who take non-steroidal anti-inflammatory medication 
regularly
8. Participants who have been prescribed statins, anticoagulants or 
fluoroquinolones within the past 3 months.
9. Participants with known allergies to diclofenac or placebo cream.
10. Participants who are unable to give informed consent.
BMI, body mass index.
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Visit 3
At the start of the third visit, participants were asked which 
treatment they thought they received, any remaining gel 
was collected from the participant, any suspected side 
effects were documented and they were asked whether 
their condition had worsened, improved or stayed the 
same. They then repeated the following procedures from 
visit 2: PPT, warm-up and hopping test. At the conclusion 
of this visit, participants were issued with their second 
tube of gel (placebo or diclofenac). They were instructed 
to wait for 1 week before using the remaining gel.
Visit 4
Their fourth appointment was scheduled within 10 days 
to 2 weeks following the second appointment, where they 
were required to repeat the same assessments.
Randomisation and blinding
A randomisation list with 32 non-blocked, unstratified 
allocations was created by a researcher (AS) using a 
simple random number generator. The same researcher 
labelled the identical-appearing gels (A or B) before 
giving them to the researcher (EB) conducting the study. 
The researcher (AS) who created the allocation list was 
not involved in any other study procedure and did not 
interact with participants. The researcher (EB) who 
conducted the study was not aware of the allocations until 
after the statistical analysis was complete.
Outcomes
The primary outcome measure was pain during tendon 
loading (single-leg hopping and numeric scale from 
0 to 10). The secondary outcomes were (A) change in 
overall symptoms, indicated by asking patients if symp-
toms had improved, worsened or stayed the same, (B) 
current pain at rest (from 0 to 10) and (C) PPT of the 
Achilles tendon. When examining the results of the 
secondary outcome ‘change in symptoms’, we noted a 
binary distribution (only one tendon worsened, whereas 
the rest either stayed the same or improved); therefore, 
this measure was collapsed into a binary outcome of 
‘improved’ or ‘worsened/stayed the same’.
Sample size
For this pilot study, we actively recruited over an 
18-month period. Sixteen adults with unilateral CAT and 
three adults with bilateral CAT participated. All available 
subjects during this period that met all the eligibility 
criteria were included in this study.
Statistics
Means (SD) are reported in the text to describe contin-
uous variables including age, height, weight, body mass 
index (BMI), VISA-A scores, symptom duration, resting 
pain and hopping pain. All calculated values are given to 
two significant figures. Frequency data were reported for 
categorical variables including sex, previous treatments 
and type of Achilles tendinopathy. All data were present 
and included, as there were no extreme outliers, and the 
data met all the assumptions for the statistical tests used. 
The primary analysis was prespecified and consisted of a 
repeat-measures linear mixed model to examine whether 
there was a statistically significant effect of type of gel 
on the outcomes, and the figures display the means and 
SEs generated by the model. The model also generated 
a series of uncorrected comparisons using the t-statistic 
(each with p<0.05) as a post hoc analysis. The following 
non-prespecified analyses were also conducted: a McNe-
mar’s test to compare paired proportions was used to 
compare the frequency of those experiencing a change 
in Achilles tendinopathy symptoms after different treat-
ments (improved vs worsen/stayed the same), and the 
OR was also calculated as an ancillary in accordance with 
the Consort statement. Spearman’s correlation was used 
to examine the association between pain and force for all 
of the conducted hopping tests. An exploratory sensitivity 
analysis was conducted to see if the bilateral cases had any 
effect on the overall results (ie, the linear mixed models 
were rerun but leaving out the cases with bilateral tendi-
nopathy; n=16). The sensitivity analysis showed that there 
was no change in significance for the major findings 
within the study. Pain during the hopping test with the 
use of diclofenac versus baseline (n=22, p=0.0003; n=16, 
p=0.0006) and pain at rest with the use of diclofenac versus 
baseline (n=22, p=0.0313; n=16, p=0.0359) remained 
significant when participants with bilateral tendinopathy 
were removed for the analysis. Finally, on examination of 
the data, we suspected the existence of a learning effect 
in the Achilles PPT measurement; therefore, we reran the 
linear mixed model to see if the visit (2, 3 or 4) exerted a 
main effect on this outcome.
RESULTS
Participants
The participant demographics are shown in table 1. A 
total of 26 participants were screened at visit 1 for eligi-
bility. After the first visit, seven of the participants did not 
qualify for the study because they did not fit the inclusion/
exclusion criteria (table 1). A total of 19 participants were 
enrolled. Primary reasons for excluding participants after 
the first visit were that their pain rating during hopping 
was 2 or below, their BMI was over 30, they were not diag-
nosed with Achilles tendinopathy or they were currently 
receiving statins. With regard to numbers analysed, three 
of the 19 participants who had bilateral CAT, and the pain 
levels and symptoms in both of their Achilles were exam-
ined separately (total of 22 Achilles), yielding n=22 for 
all analyses. No patient was excluded after randomisation.
Allocation and blinding
Twelve participants (15 tendons) received diclofenac 
at visit 2 and placebo at visit 3; the remaining seven 
participants (seven tendons) received placebo at visit 2 
and diclofenac at visit 3. Before the assessment at each 
visit, participants were asked if they thought the gel they 
received was placebo or diclofenac. Of the 19 participants, 
group.bmj.com on December 5, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
 5Bussin ER, et al. BMJ Open 2017;7:e015126. doi:10.1136/bmjopen-2016-015126
Open Access
11 correctly (four incorrectly and four unsure) identified 
the diclofenac gel, and 12 correctly (three incorrectly and 
four unsure) identified the placebo gel.
Adherence, dropouts and side effects
There were no dropouts and no drug side effects reported 
in this study. All 19 participants completed the study, and 
all data for primary and secondary outcomes were used 
from all participants, with no missing data. Seventy-nine 
per cent (15 out of 19) of all participants successfully 
brought back their diary that recorded gel application. 
Twenty-one per cent (4 out of 19) stated that they filled 
out the form properly but forgot it at home or lost it.
Effect of diclofenac and placebo on Achilles tendinopathy 
hopping pain
Figure 2 and table 2 show the rating of pain (NPRS) during 
the hopping test. At baseline the average hopping pain 
was 4.3 (95% CI 3.42 to 5.18). With the use of diclofenac, 
the average hopping pain declined to 3.1 (95% CI 2.35 
to 3.85), and with the use of placebo the average pain 
was 3.8 (95% CI 2.63 to 4.97). Despite the overlap-
ping CIs in the group means, the linear mixed model 
(which accounted for the repeated measures design) 
revealed that diclofenac resulted in a statistically signifi-
cant decrease in mean hopping pain when compared to 
baseline (p<0.001). There was no statistically significant 
difference in hopping pain between the placebo and 
diclofenac treatment, or between placebo and baseline.
Effect of diclofenac on Achilles tendinopathy symptoms and 
resting pain
Figure 3 shows the participants’ responses to the ques-
tion about whether their Achilles tendinopathy symptoms 
improved, worsened or stayed the same over the 3-day 
period of gel application. There was a significant 
(two-tailed McNemar’s test, p=0.045) trend favouring 
improvement with diclofenac treatment, with 55% of 
subjects reporting improvements in symptoms compared 
with 23% following placebo. The OR of improved symp-
toms with diclofenac versus placebo was 8.0 (95% CI 1.1 to 
350, p=0.041).
Figure 2 and table 2 show the rating of pain during rest 
on the NPRS. At baseline, the average resting pain was 
3.1 (95% CI 2.51 to 3.69), with the use of diclofenac the 
average pain was 2.3 (95% CI 1.67 to 2.93) and with the 
use of placebo the average pain was 2.7 (95% CI 1.86 to 
3.54). The change in resting pain from baseline to appli-
cation of diclofenac was statistically significant (p=0.031). 
There was no statistically significant difference in resting 
pain between the placebo and diclofenac treatment or 
between placebo and baseline.
Relation between pain and force during hopping
We conducted an ancillary analysis of the relation-
ship between the amount of force exerted during 
hopping and the amount of pain felt (NPRS). As the 
amount of pain decreased, the amount of force exerted 
during hopping increased (rs=−0.41, p<0.001).
Table 2 Achilles pain ratings
Achilles pain at rest
Baseline Diclofenac Placebo
Mean 3.1 2.3 2.7
SD 1.4 1.5 2.03
Range 0–6 0–7 0–9
p Value – 0.031* 0.10
Achilles pain during hopping test
Screening Baseline Diclofenac Placebo
Mean 4.5 4.3 3.1 3.8
SD 1.3 2.1 3.1 3.8
Range 3–7 1–7 0–7 1–9
p Value – – 0.003* 0.18
Achilles pain pressure threshold
Baseline Diclofenac Placebo
Mean (kPa) 220 270 280
SD 120 190 170
Range 50–520 98–727 72–548
p Value – 0.028* 0.089
Table 1 Participant demographics and clinical 
characteristics
Baseline characteristics of 19 participants
Variable Mean SD Range
Age (years) 48 13 24–72
Height (cm) 165 37 155–186
Weight (kg) 74 19 52–106
BMI (kg/m2) 25 3.7 19–29
VISA-A 60 12 39–76
Length of 
symptoms 
(months)
56 67 4–228
Tegner 
Activity Scale
7.0 2.0 3–10
Descriptive characteristics of 19 participants
Characteristic Number
Men 11
Women 8
Currently doing 
physiotherapy
7
No treatment 15
Descriptive characteristics of 22 Achilles
Mid-portion:insertional 15:7
Acute:overuse 2:20
Ultrasound pathology:no 
pathology
22:0
BMI, body mass index.
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Effect of diclofenac and placebo on PPT in the affected 
Achilles
Table 2 outlines the effects of the placebo and diclofenac 
on the affected Achilles tendons. There was a statisti-
cally significant difference in Achilles PPT between the 
application of diclofenac and baseline, but not with appli-
cation of placebo gel. This difference occurred despite 
the fact that the mean Achilles PPT with placebo gel was 
higher, perhaps due to a slightly larger number of indi-
viduals receiving the placebo gel as the second treatment 
(12 vs 7 participants), in combination with an apparent 
learning effect (ancillary analysis revealed that PPT values 
rose over the course of the study from visit 2 to visit 4 from 
220 to 310, p=0.028).
DISCUSSION
The purpose of this study was to determine if diclofenac 
could provide pain relief for individuals with CAT and 
to determine if a larger, adequately powered clinical 
study of this treatment incorporating a longer treatment 
course of rehabilitation would be indicated. The data 
presented here demonstrate that the majority of partici-
pants reported that their condition improved with the use 
of diclofenac. Resting pain and the PPT of the Achilles 
were also significantly improved with diclofenac, but 
not placebo. This pilot study therefore provides some 
preliminary evidence that diclofenac could be a benefi-
cial option for partial symptom relief, and a larger study 
powered to detect differences between diclofenac and 
placebo is warranted.
The force–pain relationship in this study, although 
generated via an exploratory/ancillary analysis and only 
demonstrating a moderate correlation, showed that when 
a participant was feeling less pain, they generated more 
force during hopping. Participants were free to hop at 
a self-selected pace and intensity. This finding is consis-
tent with the existing neurophysiological literature. 
Acute muscle pain of a prime mover has shown to reduce 
voluntary force and velocity performance in muscles.20 21 
However, although the pain was reduced with the use of 
diclofenac, there was no significant change in jumping 
force over the three visits. It is possible that longer term 
use of diclofenac in combination with physical rehabili-
tation could allow participants to exert more force and 
thereby achieve a faster recovery, but this hypothesis is 
very speculative, especially given concerns that the use of 
NSAIDs may interfere with exercise adaptation.22–25
This study has a number of limitations. Although 
PPT of the Achilles tendon significantly increased with 
diclofenac treatment, we also found that the PPT of the 
Achilles tendon tended to increase over the course of 
each visit, regardless of treatment allocation. This could 
be due to a learning effect, that is, participants gaining 
comfort with the test. Future studies should incorporate 
a longer period of baseline measurement to ensure that 
the PPT values are stable prior to initiating an interven-
tion. One of the biggest limitations when researching 
new treatments for CAT stems from the nature of CAT, 
Figure 2 Pain at rest and during the hopping test. Mean pain rating for the three conditions is shown; error bars represent 
the SE of the estimate. *, Significant difference in resting pain between the diclofenac and baseline, p=0.031. ø, Significant 
difference in pain between the diclofenac and baseline during the hopping test, p= 0.003. There was no significant difference 
in pain between the placebo and baseline or between diclofenac and placebo at rest or during the hopping test. NPRS, 
numeric pain rating scale. 
Figure 3 Achilles tendinopathy symptoms. Nineteen 
participants (22 Achilles) were asked if their Achilles 
symptoms improved, worsened or stayed the same over the 
3-day course of their treatment (two-tailed McNemar’s test, 
p = 0.045).
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which is characterised by fluctuating pain and a slow time 
to recovery.26 In addition to a longer period of baseline 
measurement, future studies could ask participants to 
record all the activities they participate in over the course 
of the study or, alternately, ask them to wear an activity 
monitor. This would make participants more accountable 
for their activities and researchers could take their activity 
level into consideration when analysing results.
Although this sample size was sufficient to demonstrate 
a statistically significant improvement with diclofenac 
treatment compared with baseline, a larger sample size is 
needed to examine the effectiveness of diclofenac across 
a more representative sample population, to reduce 
the possibility of type I and II errors and to specifically 
examine the potential effects of diclofenac over and 
above those achieved with placebo. For such a study, one 
could consider recruiting through rehabilitation centres 
and making patient-rated change in symptoms (improved 
vs stayed the same or worsened) a primary, binary 
outcome; assuming the results obtained in this study are 
representative, this study would require a sample size of 
72 individuals (36 per group) to have an 80% chance of 
detecting a difference in clinical improvement with 95% 
confidence. However, binary outcomes may be more 
clinically informative and less subject to bias when accom-
panied by a variety of other well-validated measures. 
For example, the VISA-A score used in this study is a 
well-validated and frequently used outcome measure that 
requires participants to rate their level of activity and the 
associated amount of pain; this score could serve as a 
useful outcome measure, as would average daily or weekly 
ratings of pain, at rest and during activity.
CONCLUSION
This pilot study explored the potential usefulness of incor-
porating an existing treatment (topical 10% diclofenac) 
into future studies of CAT rehabilitation. Because this is 
a pilot study designed to inform future research, it is not 
appropriate to generalise or consider issues of external 
validity. Pain is one of the main symptoms for patients with 
CAT, and diclofenac was apparently able to help some of 
the participants manage their Achilles pain during rest 
and tendon loading. We also learnt that patients natu-
rally generated more force during cyclic tendon loading 
(hopping) when pain was better controlled, which has 
implications for the ability to achieve positive tendon 
adaptations with exercise-based rehabilitation. Diclofenac 
is therefore a potential option to be incorporated into a 
larger study on pain and symptom relief during Achilles 
tendinopathy rehabilitation.
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